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Should heart, lung, and liver transplant
recipients receive immunosuppression
induction for kidney transplantation?
As the outcomes of solid organ transplantation
continue to improve, more heart, lung, and liver
transplant recipients will require transplantation
for end-stage renal failure. Progression to chronic
renal failure in patients with a non-renal transplant
is a morbid outcome, and is associated with a
fourfold increased risk of death (1). Renal trans-
plantation is increasingly being offered to these
patients as a means of renal replacement therapy
(2). Unfortunately, even large multi-organ trans-
plant centers have limited experience with these
complex patients, and to date, only smaller series
are available in the literature to guide decisions in
management (2–4).
Our group has struggled with decisions regarding
induction immunosuppression at the time of renal
transplant in these recipients of non-renal trans-
plants. Nationally, induction immunosuppression
is being increasingly used at the time of renal
transplant to reduce the incidence of rejection and
improve short- and long-term outcomes (5). The
potential complications of induction immuno-
suppression are well described, including infection
and malignancy. Recipients of previous non-renal
transplants are commonly considered immuno-
logically ‘‘high risk’’ with a high panel reactive
antibody (PRA), and conceptually might derive
significant benefit from induction immunosuppres-
sion to reduce rejection and improve long-term
graft function (5–9). Conversely, these same non-
renal transplant recipients are more likely to be
significantly immunosuppressed prior to renal
transplantation. This fact, together with possible
residual physiologic deficits related to their primary
disease, may render these patients more likely to be
chronically ill and at increased risk for severe
infectious complications directly related to induc-
tion immunosuppression.
We have anecdotally noted some recent poor
outcomes following induction therapy in cardiac
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Abstract: As the outcomes of heart, liver, and lung transplantation continue
to improve, more patients will present for subsequent renal transplantation.
It remains unclear whether these patients benefit from induction immuno-
suppression. We retrospectively reviewed induction on solid organ graft
recipients who underwent renal transplant at our center from January 1,
1995 to March 30, 2007. Induction and the non-induction groups were
compared by univariate and Kaplan–Meier analyses. There were 21 patients
in each group, with mean follow-up of 4.5–6.0 years. Forty-seven percent of
patients receiving induction had a severe post-operative infection, compared
with 28.6% in the non-induction group (p = NS). The one yr rejection rate
in the induction group was 9.5% compared with 14.3% for non-induction
(p = NS). One-yr graft survival was 81.0% and 95.2% in the induction and
non-induction group (p = NS). In summary, there is a trend toward lower
patient and graft survival among patients undergoing induction. These
trends could relate to selection bias in the decision to prescribe induction
immunosuppression, but further study is needed to better define the risks
and benefits of antibody-induction regimens in this population.
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transplant recipients. To better inform our center
policies, we describe our experience with induction
therapy in a group of non-renal transplant recip-
ients who receive a kidney transplant. Our hypoth-
esis is that the infectious complications in these
patients are severe and that induction should be
avoided in non-renal transplant recipients at the
time of renal transplantation.
Methods
Patients
Data collection and analysis was approved by the
University of Michigan Institutional Review
Board. All data were collected retrospectively from
the internal University of Michigan electronic
medical record. All adult patients who previously
had received a liver, lung, or heart transplant and
subsequently received a kidney transplant between
January 1, 1995 and March 30, 2007 were included
in the study group. Patients with simultaneous
kidney and liver or heart transplants were excluded
from the study. In addition, patients with insuffi-
cient data regarding whether or not they received
immunosuppression induction therapy at the time
of their kidney transplant were excluded from this
analysis (n = 4). There were two patients who
received a kidney following previous pancreas
transplant. No follow-up data were available on
one patient, and the other received only a single
dose of Atgam because of the possible anaphylactic
response. Accordingly, no kidney-after-pancreas
patients were available for inclusion in the study.
Induction therapy was considered to be present
in those who were received thymoglobulin (rabbit
anti-thymocyte globulin), Atgam (equine antithy-
mocyte globulin), or Simulect (basiliximab) at the
time of kidney transplantation. Thymoglobulin
was dosed intra-operatively at 3 mg/kg, and again
at 2 mg/kg on post-operative day 2. Post-operative
doses were decreased by 50% in three patients with
white blood cell counts of 1500–3000 cells/micro-
liter, but all patients complete full courses. Basil-
iximab induction consisted of two 20 mg doses.
Atgam therapy was composed of 20 mg infu-
sions daily for 10 days. Indications for induction
therapy were African American race, documented
PRA >30%, minimal immunosuppression follow-
ing initial transplant, or receipt of a living unre-
lated donor organ, with final decisions on inclusion
made by the operative surgeon. All patients
enrolled in induction therapy completed their
prescribed course, with dose adjustments for
leukopenia as necessary in the thymoglobulin
group.
Maintenance therapy was comprised of a calci-
neurin inhibitor, mycophenylate mofetil, and a
prednisone taper. Cyclosporine was used in the
majority of non-induction patients (17/21, 81%),
with one patient receiving sirolimus, and a total of
four receiving tacrolimus (one crossover for
intolerance of cyclosporine). In the induction
group, cyclosporine was also the most common
calcineurin inhibitor (13/21, 62%). Two patients
received sirolimus, and a total of nine (43%, with
three crossovers from cyclosporine) received
tacrolimus.
For subsequent analysis, the exposure variable
was receipt of antibody induction immunosuppres-
sion at the time of renal transplantation. Compar-
isons between the two groups included: clinical
characteristics, maintenance immunosuppression
regimen, readmission data, the incidence of infec-
tions, rejection, and cancer, as well as patient and
graft survival. Readmission data included only
those readmissions that occurred at the University
of Michigan. All patients with biopsy-proven
rejection (Banff 2A of greater) were readmitted
for initiation of anti-rejection therapy.
Statistical analysis
The association of donor, recipient, and transplant
characteristics between the induction and the non-
induction groups were compared by univariate
analysis. Categorical variables were analyzed using
chi-square analysis. Continuous variables were
assessed with a two-tailed Student’s t-test. Unad-
justed rates of graft failure and patient survival
were calculated by the method of Kaplan and
Meier (10). The data were analyzed using spss
software (version 15.0, SPSS Inc., Chicago, IL,
USA).
Results
A total of 42 patients fulfilled inclusion criteria for
this analysis. The reason for development of end-
stage renal disease was either wholly or partly
ascribed to calcineurin inhibitor toxicity in 22 of
the 42 patients, with causes for renal failure in the
remainder including diabetic nephropathy (8),
hypertension (1), and acute tubular necrosis (4),
Twenty-one of these kidney transplant recipients
received induction at the time of transplant, and
the remaining 21 patients did not receive induction.
The patient characteristics of these two study
groups are detailed in Table 1. The majority of
the primary transplants were for end-stage liver
disease – 67% for the induction group and 71% for
the non-induction group. There was a significantly
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higher proportion of deceased donor kidney trans-
plants in the induction group. The 21 patients that
received induction immunosuppression at the time
of the kidney transplant were dosed with either
anti-thymocyte globulin (thymoglobulin, 67%,
n = 14), lymphocyte immune globulin (Atgam,
24%, n = 5), or basiliximab (Simulect, 10%,
n = 2). The panel reactive antibody scores at time
of transplant in the induction group were hetero-
geneous, with PRA <10 in 28.5%, PRA 10–40 in
28.5%, and PRA >40 in the remaining 43%.
In general, a higher percentage of patients that
received induction immunosuppression at the time
of the kidney transplant were readmitted within the
first year following a kidney transplant, but no
comparisons reached statistical significance. One
more patient was readmitted for treatment of
rejection in the non-induction group than in the
induction recipients (14.3% vs. 9.5%, p = NS). A
comparison of the reasons for readmissions is
graphically represented in Fig. 1.
There was a tendency toward more readmissions
for infection in the induction group compared with
the non-induction group. A total of 23 infectious
complications were noted in 16 patients. In the
induction group, there were 14 infections in 10
patients, of which five were infections of the
respiratory tract, one was a urinary tract infection,
two were of intra-abdominal origin, three were
related to surgical site infection, two others were
viral gastroenteritis, and one other to CMV colitis.
Six non-induction patients suffered a total of nine
events, comprised of two respiratory infections,
two urinary tract infections, three intra-abdominal
infections, and two cases of viral gastroenteritis. Of
note, no polyoma virus-related infections were
documented in either group.
Patient outcomes with regard to renal transplant
are summarized in Table 2. Delayed graft function
was more common in the induction group (47.6%
vs. 9.5%, OR = 5.0, 95%CI 1.24–20.1). No
statistically significant differences were noted in
patient and graft outcomes between the induction
and the non-induction groups, though there was a
moderately lower rate of patient and graft survival
in the induction group at one yr. Of note, there was
no early graft loss in patients surviving more than
one yr post-transplant. Causes for eventual graft
failure listed in the ‘‘other’’ category of Table 2
included chronic fibrosis (n = 1, induction group),
recurrence of primary disease (one patient in each
group), possible calcineurin inhibitor toxicity
(n = 1, induction group), and unknown cause
(one patient, induction group).
Table 1. Comparison of the clinical character-
istics between two groups of liver, heart, and
lung transplant patients who received either
induction therapy or did not at the time of kidney
transplantation
Induction (n = 21) Non-induction (n = 21) p-values
Age at kidney
transplant
43.0 ± 14.5 46.6 ± 11.2 0.36
Sex 66.7% male (14) 71.4% male (15) 0.74
Race 90.5% non-black (19) 100% non-black (21) 0.15
Diabetic 38.1% (8) 52.4% (11) 0.35
Previous transplant
Heart 7 (33.3%) 4 (19.0%) 0.24
Lung 0 2 (9.5%)
Liver 14 (66.7%) 15 (71.4%)
Years from primary
transplant
7.4 ± 5.5 8.2 ± 5.8 0.65
Mean follow-up
since kidney transplant
4.5 ± 4.2 6.0 ± 3.8 0.26
Transplant type
Living donor 4 (19.1%) 14 (66.7%) 0.001*
Deceased donor 17 (80.9%) 4 (33.3%)
Mean PRA 36 ± 39 21 ± 13 0.09
Fig. 1. The percentage of patients in the induction and in the
non-induction groups who were readmitted within the first year
after kidney transplant for either an infection or rejection
(Banff 2A rejection or greater). p > 0.05 for all comparisons.
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Primary organ (heart, lung, liver) survival was
also analyzed in the two groups. Among the forty-
two patients, there was only one primary graft loss
in the non-induction group, which was a recur-
rence of hepatitis C virus in a transplanted liver,
ultimately leading to the patients demise. No
primary organs were lost in the induction group.
Long-term patient survival (Fig. 2) and graft
survival (Fig. 3) were estimated using Kaplan–
Meier survival analysis. In both the induction and
the non-induction groups, survival declined at
approximately equivalent rates. The survival rate
for induced patients is consistently lower than that
of non-induced patients, though this difference did
not extend to a statistically significant degree. The
graft survival curves demonstrate similar out-
comes, and these data again were not statistically
significant between induction and non-induction
groups. There were four deaths within the first year
in the induction group, all of whom had received
thymoglobulin.
Discussion
With this study, we report on the outcomes of 42
kidney transplant patients who had previously
received a non-renal solid organ transplant. Our
analysis attempts to answer the question of
whether these patients should receive induction
immunosuppression at the time of kidney trans-
plant. Our findings note higher delayed graft
function and lower patient and graft survival in
the group of patients that received induction
therapy. As expected, the group of patients that
received induction immunosuppression also had
more infections and less rejection than the group of
patients that did not receive induction. The
disparity between patient and graft survival are
shown in Figs. 2 and 3 is largely the result of four
deaths in the first year in the induction group. Each
of these patients had at least one readmission for
infection, and three of the four died in the setting
of sepsis. Rejection was an infrequent occurrence,
and slightly less common in the induction group.
The induction group had an approximately fivefold
higher rate of delayed graft function than non-
induction patients, but the elevated delayed graft
function (DGF) risk associated with the higher
proportion of deceased donors in this group is a
more likely etiology of DGF than effect related to
induction medications. The complexities of patient
outcomes in this setting underscore the need to
carefully weigh the risks and benefits of induction
immunosuppression in these chronically ill
transplant recipients.
Fig. 2. Kaplan–Meier curves detailing patient survival among
previous heart, lung, or liver transplant recipients who did or
did not receive immunosuppressive induction at the time of
kidney transplant (p = 0.12).
Fig. 3. Kaplan–Meier curves detailing long term kidney
transplant graft survival among previous heart, lung, or liver
transplant recipients who did or did not receive immunosup-
pressive induction at the time of kidney transplant (p = 0.32).
Table 2. Summary of the one-yr patient and graft outcomes among 42
heart, lung, and liver transplant recipients who either did or did not receive






(n = 21) p-values
Delayed graft function 47.6 9.5 0.004*
One yr graft survival 81.0 95.2 0.15
One yr patient survival 81.0 95.2 0.15
Cause of death infection 14.3 (3) 9.5 (2) 0.47
Cause of death cancer 4.8 (1) 4.8 (1) 0.47
Reason for graft loss n = 8 n = 6 0.39
Rejection 12.5 (1) 33.3 (2)
Death 37.5 (3) 50.0 (3)
Other 50.0 (4) 16.7 (1)
The bold and ‘*’ highlights value with a signficant (<0.05) p-value.
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The long-term survival of liver, heart, and lung
transplant patients continues to improve (11, 12).
These patients face many potential long-term
complications following solid organ transplanta-
tion, including end-stage renal disease. Specifically,
chronic renal failure developed at approximately
16.5% of solid organ transferred recipients over a
median follow-up time of 36 months. Our center
and others are increasingly seeing non-renal solid
organ transplant recipients for evaluation for
kidney transplantation (2). The patient and graft
survival of this select group of patients is an
emerging area of study. The largest report in the
literature contained 18 solid organ transplant
recipients who went on to receive kidney trans-
plants (3). In general, this study and smaller studies
have reported excellent results with respect to
patient and renal allograft survival inclusive of a
variety of immunosuppressive strategies (3, 4).
There have been no previous reports specifically
pertaining to the management of induction immu-
nosuppression in patients with previous non-renal
transplants who go on to require kidney transplan-
tation. There is a significantmovement in theUnited
States toward increased utilization of induction
immunosuppression at the time of kidney trans-
plantation (5). Our center reserves induction immu-
nosuppression for patients with a PRA >30%,
African American recipients, non-immunosup-
pressed recipients of a prior solid organ graft, and
recipients of living unrelated kidney transplants.
Even though a significant number of previous non-
renal solid organ transplant recipients fulfill our
center-specific criteria to receive induction immu-
nosuppression, we have been concerned about
giving such potent immunosuppression to this
patient population. Several recent poor outcomes
in patients who have received induction immuno-
suppression served as the impetus for this study.
Our series of 42 patients is the largest report of
renal transplant following previous non-renal solid
organ transplant, and is the first to focus on the use
of induction immunosuppression in these complex
patients. Even though our group has this relatively
large experience, this analysis is underpowered to
clearly determine whether recipients of a previous
non-renal transplant should receive induction at
the time of a kidney transplant. Recipients of
induction therapy had less rejection, but overall
had more infections, and worse survival. All four
early deaths in the induction group were in patients
who had received thymoglobulin. It remains
unclear whether these poor outcomes are indepen-
dently related to induction immunosuppression, or
are related to other patient-specific factors. A
higher percentage of the non-induction group
received kidneys from living donors, though the
reasons for this disparity are not clear. Data
previously developed at our center, and were
consistent with multiple reports in the literature,
links living-donor organ transplant to better short-
and long-term outcomes. The reasons for this
advantage are likely manifold, beginning with
shorter mean time on dialysis, smoother peri-
operative course, and better social support struc-
ture following transplantation. All of these factors
have been shown to significantly impact kidney
transplant outcomes (13, 14), and could affect our
result. Certainly, the higher rate of deceased donor
renal transplant in the induction group confounds
analysis of the disparity in delayed graft function
rates. Another potential confounding factor in-
cludes the indications for induction therapy. By
protocol, recipients of induction therapy are at a
higher immunologic risk for rejection. Physician
discretion plays a role in this decision making,
however, and could make the difference between
inclusion and standard therapy. Conversely, some
patients who by PRA criteria meet requirements
for induction therapy were thought to be too frail,
and were not given induction immunosuppression.
The size of our series does not allow for a robust
multivariable analysis that would control for such
confounding influences. In addition, the retrospec-
tive nature of this analysis does not allow full
investigation regarding the reasons patients were
placed in the induction or non-induction group. A
significantly larger sample size would also allow
exploration of the relative superiority of one type
of induction therapy in this population.
Although currently there is a relatively small
number of patients receiving kidneys after previous
solid organ transplants (approximately 2% of
kidney transplant recipients at our center), this
group of patients will undoubtedly continue to
expand. When deciding upon induction immuno-
suppression, transplant physicians must carefully
consider chronic medical conditions, degree of
immunosuppression prior to kidney transplant,
risk of an infectious complication, and the
potential morbidity associated with acute cellular
rejection. Even though our study is quite limited by
both the complexity of the patients and the small
sample size, induction immunosuppression does
seem to be associated with poor short-term out-
comes compared with the non-induction immuno-
suppression. Specifically, infectious complications
in the induction group were more common, and
overall of higher acuity, than in non-induction
counterparts. Similarly, this limited analysis does
not suggest any long-term benefits from induction
immunosuppression. Induction immunosuppression
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should be reserved for high immunologic risk
categories in previous recipients of a non-renal
solid organ transplant. In the absence of large
enough series to validate specific numerical cutoffs
for PRA score or other criteria, decisions on
induction will continue to be heavily reliant on
physician discretion. As such, a multi-disciplinary
group, including a practitioner who manages the
patients long-term immunosuppression prior to
the kidney transplant, will be beneficial when
ultimately deciding whether or not to give these
complicated patients antibody induction immuno-
suppression.
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